Physician profile
Bryan L Woods
NPI 1063416634
$5,921.85
in general payments reported to CMS, 2019-2025
33 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $332 · 2021: $252 · 2022: $610 · 2023: $1,001 · 2024: $1,532 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,361.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.76 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $985.21 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $691.83 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $343.14 | 2022-2025 | Epclusa |
| Janssen Biotech, INC. | $263.28 | 2019-2025 | Stelara, Tremfya, Simponi |
| Braintree Laboratories, INC. | $251.77 | 2019-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $184.80 | 2019-2023 | Linzess |
| Qol Medical, LLC | $173.70 | 2023-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $173.68 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $153.19 | 2019-2022 | |
| Romark Laboratories, Lc | $147.45 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $147.45 | 2023-2025 | Dupixent |
| Genzyme Corporation | $143.55 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $131.15 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $128.25 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $124.90 | 2019-2024 | Dificid |
| Pfizer INC. | $101.93 | 2019-2024 | |
| Organon LLC | $74.21 | 2023-2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $74.18 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $70.86 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $55.90 | 2023-2025 | Omvoh |
| Boston Scientific Corporation | $53.89 | 2019-2022 | |
| Allergan, INC. | $49.47 | 2019-2020 | |
| Pentax of America, INC. | $41.65 | 2021-2022 | |
| Amgen INC. | $33.39 | 2022 | |
| Celgene Corporation | $31.99 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $31.78 | 2023-2024 | Idacio |
| Axonics, INC. | $25.72 | 2024 | Axonics |
| Ardelyx, INC. | $22.21 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $15.90 | 2022 | |
| Esperion Therapeutics, INC. | $14.86 | 2020 | |
| Shionogi INC | $13.34 | 2019 | |
| Alfasigma USA, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.